Literature DB >> 19559793

Correlates of arterial stiffness in an ageing population: role of asymmetric dimethylarginine.

Doan T M Ngo1, Aaron L Sverdlov, John J McNeil, John D Horowitz.   

Abstract

A number of previous investigators have demonstrated that arterial augmentation index (AIx), a measure of apparent arterial stiffness, reflects in part vascular endothelial function, and that AIx is modulated by nitric oxide (NO) responses. We evaluated AIx in a population of 253 ageing subjects (mean age 63.4+/-6 (standard deviation, SD) years) and its relationship to (i) plasma levels of asymmetric dimethylarginine (ADMA), a marker and mediator of vascular endothelial dysfunction and (ii) the ratio of ADMA to its non-metabolised enantiomer symmetric dimethylarginine (SDMA), an inverse index of ADMA metabolic clearance. Evaluation was performed by univariate followed by multivariate analyses. On multivariate analyses, both ADMA (beta=0.16, p=0.01) and ADMA:SDMA (beta=0.21, p<0.001) ratio were significant direct correlates of AIx. Other significant correlates of AIx on multivariate analysis were: use of angiotensin-converting enzyme inhibitors/angiotensin-receptor blockers (ACEi/ARB) (beta=-0.24, p=0.004), smoking history (beta=0.15, p=0.007), male gender (beta=-0.38, p<0.001), creatinine clearance (CrCL) (beta=-0.25, p<0.001), and history of hypertension (beta=0.17, p=0.04). We conclude that (1) endothelial dysfunction engendered by impairment of NO synthesis may represent the basis for increased arterial stiffness in ageing individuals and (2) the fundamental biochemical anomaly may be impairment of ADMA clearance. These pathophysiological factors are likely to be relevant to optimize therapy to ameliorate disorders of arterial compliance in the ageing population.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19559793     DOI: 10.1016/j.phrs.2009.06.006

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  6 in total

1.  Arterial wave reflection and aortic valve calcification in an elderly community-based cohort.

Authors:  Fusako Sera; Cesare Russo; Shinichi Iwata; Zhezhen Jin; Tatjana Rundek; Mitchell S V Elkind; Shunichi Homma; Ralph L Sacco; Marco R Di Tullio
Journal:  J Am Soc Echocardiogr       Date:  2015-01-15       Impact factor: 5.251

2.  Aging of the nitric oxide system: are we as old as our NO?

Authors:  Aaron L Sverdlov; Doan T M Ngo; Wai P A Chan; Yuliy Y Chirkov; John D Horowitz
Journal:  J Am Heart Assoc       Date:  2014-08-18       Impact factor: 5.501

3.  Relationship between plasma asymmetric dimethylarginine and nitric oxide levels affects aerobic exercise training-induced reduction of arterial stiffness in middle-aged and older adults.

Authors:  Mio Shimomura; Shumpei Fujie; Kiyoshi Sanada; Hiroki Kajimoto; Takafumi Hamaoka; Motoyuki Iemitsu
Journal:  Phys Act Nutr       Date:  2021-03-31

4.  Impact of ADMA, endothelial progenitor cells and traditional cardiovascular risk factors on pulse wave velocity among prediabetic individuals.

Authors:  Ioannis Protopsaltis; Stefanos Foussas; Angeliki Angelidi; Angelos Gritzapis; Theodoros Ν Sergentanis; Spyros Matsagos; Konstantinos Tzirogiannis; Georgios I Panoutsopoulos; Georgios Dimitriadis; Sotirios Raptis; Andreas Melidonis
Journal:  Cardiovasc Diabetol       Date:  2012-11-15       Impact factor: 9.951

5.  Roles of insulin, age, and asymmetric dimethylarginine on nitric oxide synthesis in vivo.

Authors:  Paolo Tessari; Diego Cecchet; Carlo Artusi; Monica Vettore; Renato Millioni; Mario Plebani; Lucia Puricelli; Monica Vedovato
Journal:  Diabetes       Date:  2013-03-08       Impact factor: 9.461

6.  Asymmetric dimethylarginine is not a marker of arterial damage in children with glomerular kidney diseases.

Authors:  Piotr Skrzypczyk; Joanna Przychodzień; Małgorzata Mizerska-Wasiak; Elżbieta Kuźma-Mroczkowska; Anna Stelmaszczyk-Emmel; Elżbieta GóRSKA; Małgorzata Pańczyk-Tomaszewska
Journal:  Cent Eur J Immunol       Date:  2020-01-20       Impact factor: 2.085

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.